Andere Sprachen Verve Therapeutics, Inc.

Aktien

A3CSHT

US92539P1012

VERV

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
6,64 ^USD	-0,30 %		-12,63 %	-52,37 %

03.04.	VERVE THERAPEUTICS, INC. : Bewertung von Stifel Nicolaus zum Kaufen erhalten	ZM
02.04.	Sektor-Update: Aktien des Gesundheitswesens rutschen am späten Nachmittag ab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws	19.04.
Sector Update: Health Care Stocks Slide Late Afternoon	02.04.
Top Midday Decliners	02.04.
Looming Factory Orders, Job Openings Data Prompt Lower Premarket Action for US Equity Futures	02.04.
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	02.04.
Sector Update: Health Care	02.04.
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell	02.04.
Top Premarket Decliners	02.04.
Verve Therapeutics Announces Updates on its PCSK9 Program	02.04.
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels	02.04.
Verve Therapeutics, Inc. Announces Updates on its PCSK9 Program	02.04.
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	28.03.
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01.03.
Verve Therapeutics Q4 Net Loss Widens, Collaboration Revenue Rises; Beats Estimates; Shares Rise	27.02.
Verve Therapeutics: Q4 Earnings Snapshot	27.02.
Verve Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	27.02.
Verve Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01.02.
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Verve Therapeutics, Inc.

Aktien

A3CSHT

US92539P1012

VERV

Andere Sprachen

Filter